Aim
The aim was to compare the pathological complete response (pCR) rate at 8 compared to 12 weeks’ interval between completion of neoadjuvant chemoradiotherapy (CRT) and surgery in patients with locally advanced rectal cancer.
Method
This was a randomized trial which included a total of 330 patients from two institutions. Patients with locally advanced (T3‐4N0M0, TxN+M0) rectal cancer were randomized into 8‐ and 12‐week interval groups. All the patients received long‐course CRT (45 Gy in 1.8 Gy fractions and concomitant oral capecitabine or 5‐fluorouracil infusion). Surgery was performed at either 8 or 12 weeks after CRT. The primary end‐point was pCR. Secondary end‐points were sphincter preservation, postoperative morbidity and mortality.
Results
Two‐hundred and fifty‐two patients (n = 125 in the 8‐week group, n = 127 in the 12‐week group) were included. Demographic and clinical characteristics were similar between groups. The overall pCR rate was 17.9% (n = 45): 12% (n = 15) in the 8‐week group and 23.6% (n = 30) in the 12‐week group (P = 0.021). Sphincter‐preserving surgery was performed in 107 (85.6%) patients which was significantly higher than the 94 (74%) patients in the 12‐week group (P = 0.016). Postoperative mortality was seen in three (1.2%) patients overall and was not different between groups (1.6% in 8 weeks vs 0.8% in 12 weeks, P = 0.494). Groups were similar in anastomotic leak (10.8% in 8 weeks vs 4.5% in 12 weeks, P = 0.088) and morbidity (30.4% in 8 weeks and 20.1% in 12 weeks, P = 0.083).
Conclusion
Extending the interval between CRT and surgery from 8 to 12 weeks resulted in a 2‐fold increase in pCR rate without any difference in mortality and morbidity.
Stigmaeus erzincanus sp. nov. collected from soil and litter under Pinus sylvestris, Erzincan, Turkey is described and illustrated here. This species can clearly be distinguished by having apodemal marking, eyes and pob absent, one pair of extra and non-setose dorsal shields, suranal shield entire, genual setal formula 5(+1κ)-5-2-2, terminal eupathidion on palpal tarsus trident, IVω present.http://zoobank.org/urn:lsid:zoobank.org:pub:958FBE0C-859A-45C9-B730-998F65506FD7
In this study, asymmetric variations in dorsal and ventral body setae in some adult females in three species of the genus Raphignathus Dugès; R. gracilis (Rack), R. hecmatanaensis Khanjani & Ueckermann and R. kuznetzovi Doğan & Ayyıldız were given and photographed. Records on asymmetric variations in Raphignathus species found in the literature were also reviewed.
Based on the mite specimens collected within the scope of a study on Erzincan (Turkey) mite biodiversity, two species of the genus Stigmaeus are described and illustrated here: S. bifurcus sp. nov. as new to science and S. miandoabiensis Bagheri & Zarei, 2012 as a new record for Turkey. Some morphological abnormalities in the new species are noted. The deutonymph of S. miandoabiensis is described for the first time in this study. Discovery of this stage from soil and litter under Pinus sylvestris in Turkey adds more data to our knowledge of the species.
Redescription of Stigmaeus solidus Kuznetsov (Acari, Stigmaeidae) was given based on the specimens collected from Turkey and The Netherlands, its original figures were illustrated, and distribution in the world of the species was emphasized. Some structural variations on setae h2 in the female were observed. Male and deutonymph of this species were included for the first time in this study. S. solidus was given before from the type locality, Russia, and reported previously from Kelkit Valley in Turkey. It is determined that this was newly recorded species for the Dutch mite fauna and for the second time from Harşit Valley with this study.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.